FREQUENTLY ASKED QUESTIONS

EPCLUSA (sofosbuvir/velpatasvir) is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C genotype 1-6 infection with or without cirrhosis (compensated).^1,2

Please see our full Prescribing Information or Package Insert for complete details.

Yes. EPCLUSA can be used to treat chronic HCV in people who inject drugs regardless of active drug use or use of medication for opioid use disorder (MOUD).¹

Learn more about EPCLUSA efficacy in people who inject drugs.¹

Yes. A clinical study of EPCLUSA in people who inject drugs included patients who experienced adherence challenges or demonstrated imperfect adherence during treatment.³

Learn more about EPCLUSA efficacy in people who inject drugs.³

Yes. EPCLUSA does have information on drug interactions that may occur if patients are taking concomitant medications.¹

Learn more about the safety profile of EPCLUSA, which includes information about drug interactions, on the EPCLUSA safety page.

Yes. Clinical studies of EPCLUSA included patients on concurrent MOUD treatment (methadone and buprenorphine/naloxone).¹

Learn more about EPCLUSA efficacy in people who inject drugs.¹

EPCLUSA (sofosbuvir/velpatasvir) can be used in the treatment of chronic hepatitis C virus in adult patients with¹:

• No cirrhosis
• Compensated cirrhosis
• Decompensated cirrhosis in combination with ribavirin
• HCV/HIV-1 coinfection
• Treatment-naïve and treatment-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis
• Severe renal impairment, including end-stage renal disease requiring dialysis
• People who inject drugs, including those on medication for opioid use disorder

EPCLUSA is also approved for use in pediatric patients 3 years and older without cirrhosis or with compensated cirrhosis.¹

Learn more about EPCLUSA in the full Prescribing Information or Package Insert.

EPCLUSA (sofosbuvir/velpatasvir) should be taken once daily for 12 weeks.¹

Learn more about EPCLUSA dosing.

In patients without cirrhosis or with compensated cirrhosis, EPCLUSA can be taken once daily for 12 weeks with or without food.¹

Learn more about how to take EPCLUSA.

EPCLUSA has a Boxed Warning on the risk of HBV reactivation in HCV/HBV coinfected patients. Hepatitis B (HBV) reactivation has been reported in HCV/HBV coinfected patients who were undergoing or completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Patients should be tested for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA.¹

Learn more about the Boxed Warning on the risk of HBV reactivation and EPCLUSA safety.¹

No, EPCLUSA does not contain a protease inhibitor. Sofosbuvir/velpatasvir is the only protease inhibitor–free, pangenotypic, panfibrotic HCV regimen.^1,4

Commercial patients may pay as little as $5 per co-pay with EPCLUSA or its Authorized Generic (sofosbuvir/velpatasvir).^5,a

^aTerms and conditions apply. See details here.

Learn more about EPCLUSA financial support.

EPCLUSA is the only protease-inhibitor free, pangenotypic, single-tablet regimen for the treatment of HCV. EPCLUSA contains sofosbuvir, an NS5B inhibitor that acts as a chain terminator. It also contains velpatasvir, an NS5A inhibitor. NS5A and NS5B proteins play key roles in the replication of viral HCV RNA.^1,6

Once activated, sofosbuvir acts by inhibiting the HCV NS5B polymerase, terminating the HCV RNA chain. Velpatasvir targets the NS5A protein, which plays a key role in viral assembly and replication. When combined, EPCLUSA interferes with viral HCV replication.^1,6

Please see our full Prescribing Information or Package Insert for additional details.

Hepatitis C is a disease caused by an infection of the liver with the hepatitis C virus (HCV), which is blood-borne. HCV can range from a short-term illness (acute) to a serious, long-term illness (chronic). Acute HCV occurs within the first 6 months after someone is exposed to the hepatitis C virus and can lead to chronic hepatitis C. Chronic hepatitis C can cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death.²

According to the latest AASLD/IDSA guidelines, routine one-time, opt-out testing is recommended for all adults 18 years or older. Testing is also recommended for all people, including those under 18 years old, who have past or current injection drug use or intranasal drug use.⁷

Visit the AASLD/IDSA guidelines to learn more about HCV treatment recommendations.

Diagnosing and treating a patient with hepatitis C involves some clear steps.

Please refer to the treatment flowchart for guidance on diagnosis of hepatitis C and when to initiate treatment.